Literature DB >> 21612547

Early end for FEM-PrEP HIV prevention trial.

.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21612547     DOI： 10.1089/apc.2011.9874

Source DB:  PubMed          Journal:  AIDS Patient Care STDS        ISSN： 1087-2914            Impact factor:   5.078


× No keyword cloud information.
  10 in total

1.  Are we prepped for preexposure prophylaxis (PrEP)? Provider opinions on the real-world use of PrEP in the United States and Canada.

Authors:  Maile Y Karris; Susan E Beekmann; Sanjay R Mehta; Christy M Anderson; Philip M Polgreen
Journal:  Clin Infect Dis       Date:  2013-12-06       Impact factor: 9.079

2.  Assessment of peer-based and structural strategies for increasing male participation in an antenatal setting in Lilongwe, Malawi.

Authors:  Steve M Mphonda; Nora E Rosenberg; Esmie Kamanga; Innocent Mofolo; Gertrude Mwale; Edson Boa; Mwawi Mwale; Francis Martinson; Irving Hoffman; Mina C Hosseinipour
Journal:  Afr J Reprod Health       Date:  2014-06

3.  HIV incidence in young girls in KwaZulu-Natal, South Africa--public health imperative for their inclusion in HIV biomedical intervention trials.

Authors:  Quarraisha Abdool Karim; Ayesha B M Kharsany; Janet A Frohlich; Lise Werner; Mukelisiwe Mlotshwa; Bernadette T Madlala; Salim S Abdool Karim
Journal:  AIDS Behav       Date:  2012-10

4.  The Promise of Antiretrovirals for HIV Prevention.

Authors:  Charlene Flash; Douglas Krakower; Kenneth H Mayer
Journal:  Curr Infect Dis Rep       Date:  2012-04       Impact factor: 3.725

5.  Preexposure prophylaxis is efficacious for HIV-1 prevention among women using depot medroxyprogesterone acetate for contraception.

Authors:  Renee Heffron; Nelly Mugo; Edwin Were; James Kiarie; Elizabeth A Bukusi; Andrew Mujugira; Lisa M Frenkel; Deborah Donnell; Allan Ronald; Connie Celum; Jared M Baeten
Journal:  AIDS       Date:  2014-11-28       Impact factor: 4.177

6.  Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011.

Authors:  Nicolas Ruffin; Marie Borggren; Zelda Euler; Fabio Fiorino; Katrijn Grupping; David Hallengärd; Aneele Javed; Kevin Mendonca; Charlotte Pollard; David Reinhart; Elisa Saba; Enas Sheik-Khalil; Annette Sköld; Serena Ziglio; Gabriella Scarlatti; Frances Gotch; Britta Wahren; Robin J Shattock
Journal:  J Transl Med       Date:  2012-07-11       Impact factor: 5.531

7.  The use of preexposure treatments for HIV prophylaxis.

Authors:  Adrian Majid; Robert R Redfield; Bruce L Gilliam
Journal:  HIV AIDS (Auckl)       Date:  2012-02-03

8.  Pharmacokinetics and pharmacodynamics of the reverse transcriptase inhibitor tenofovir and prophylactic efficacy against HIV-1 infection.

Authors:  Sulav Duwal; Christof Schütte; Max von Kleist
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

Review 9.  HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research.

Authors:  Daniel J Escudero; Mark N Lurie; Thomas Kerr; Chanelle J Howe; Brandon D L Marshall
Journal:  J Int AIDS Soc       Date:  2014-03-27       Impact factor: 5.396

10.  Uptake of tenofovir and emtricitabine into non-monocytic female genital tract cells with and without hormonal contraceptives.

Authors:  Amanda Marie James; Jennifer R King; Ighovwerha Ofotokun; Anandi N Sheth; Edward P Acosta
Journal:  J Exp Pharmacol       Date:  2013-08-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.